The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

Znanstveni rad - Izvorni znanstveni rad

• Autor: Nikolina Jovanović
• Autor: Nada Božina
• Autor: Mila Lovrić
• Autor: Vesna Medved
• Autor: Miro Jakovljević
• Autor: Alma Mihaljević Peleš
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti

Sažetak (engleski)

PURPOSE:

To evaluate the role of cytochrome 450 2D6 (CYP2D6) and ABCB1 variants on plasma risperidone concentrations and treatment response in 83 drug-naive patients experiencing a first episode of psychosis. ----- METHODS:

All patients were treated with risperidone for 8 weeks. The CYP2D6 genotyping was performed by allele-specific PCR-restriction fragment length polymorphism analysis (for alleles *3,*4,*6) and long-distance PCR (for duplications and allele *5), while real-time PCR analysis was used for the ABCB1 G2677T/A and C3435T variants. Plasma concentrations of risperidone and 9-OH risperidone were measured by high-performance liquid chromatography. ----- RESULTS:

The number of patients with the CYP2D6 wild type (wt)/wt, wt/mutation (mut) and mut/mut genotype was 43, 32 and 8, respectively. The number of patients with the ABCB1 2677G/G, G/T and T/T variants was 29, 42 and 12, respectively; those with the 3435CC, C/T and T/T variants was 25, 37 and 21, respectively. The CYP2D6 genotype had a strong effect on the steady-state dose-corrected plasma levels (C/D) of risperidone, its 9-OH metabolite and the active moiety, while the ABCB1 2677 T/T and 3435 T/T genotypes has similarly strong effects on the active moiety C/D. The CYP2D6 poor metabolizers had a significantly higher risperidone C/D and active moiety C/D and lower 9-OH risperidone C/D. The ABCB1 3435 T allele and the ABCB1 2667 T-3435 T haplotype carriers were more frequent among subjects without extrapyramidal syndromes. Patients showed significant improvements in positive and general symptoms, but not in negative symptoms. These changes were not related to variations in genetic and drug concentration data. ----- CONCLUSION:

Our findings suggest that CYP2D6 and ABCB1 G2677T and C3435T may be useful determinants of risperidone plasma concentrations, but the clinical implications of these associations in relation to treatment response and side-effects remain unclear.

• Ključne riječi (engleski): Adult; Antipsychotic Agents/administration & dosage; Antipsychotic Agents/adverse effects; Antipsychotic Agents/blood; Antipsychotic Agents/pharmacokinetics; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6/genetics; Cytochrome P-450 CYP2D6/metabolism; Female; Genotype; Humans; Isoxazoles/blood; Male; Middle Aged; Mutation; P-Glycoprotein/genetics; P-Glycoprotein/metabolism; Pyrimidines/blood; Risperidone/administration & dosage; Risperidone/adverse effects; Risperidone/blood; Risperidone/pharmacokinetics; Sample Size; Schizophrenia/drug therapy; Schizophrenia/enzymology; Schizophrenia/metabolism; Treatment Outcome
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Izvorni znanstveni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Završna verzija rukopisa prihvaćena za objavljivanje (postprint)
• Naslov časopisa: European Journal of Clinical Pharmacology
• Brojčani podaci: vol. 66, br. 11, str. 1109-1117
• p-ISSN: 0031-6970
• DOI: https://doi.org/10.1007/s00228-010-0850-1
• URN:NBN: urn:nbn:hr:105:575669
• Datum objave publikacije: 2010-11
• URL dokumenta: https://doi.org/10.1007/s00228-010-0850-1
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2024-03-27 19:10:24